hawaii - you've posted that or v similar several times over an extended period. We get it. But can't do anything about it now - even MC can't, even if he regrets it.
The best answer is for MC to generate some meaningful progress. We are on the cusp, and I hope that the continuing silence from the company into a quarter when we are expecting significant developments (only thing we get seems to be by PIs digging around trying to find titbits ..) is a good sign.
But I do agree, its been a poor show for a long time now - exceptionally disappointed by MC and his seeming contempt for ordinary PIs, and just hoping that the results which are eventually generated for the big investors and MC himself benefit us lowlife too.
Ophidian - pleased to hear that. You were quite vocal about the 'gap' at 80p recently. I think that unsettled a few because you seem to have quite a following. So keen to know what's changed in your thinking if you don't mind sharing.
Noix - thanks for this research. And great to remember this is just 1 of numerous workstreams at different stages of development. 1000+ patents and same again in application, and the MicroRx platform helping identify new targets - should be no shortage of future pipeline.
I wonder if anyone ever thought of offering the land owners a share of profits, in perpetuity i.e. a kind of royalty. Could be a miniscule proportion of the sums generated but still life-changing for the land owners and their families now and into the future. They would also have a stake in making and keeping it a success.
RE: I found this really interesting18 Oct 2020 13:10
trendz - thanks for sharing, agree, a helpful intro. I recently signed up to do the (free!) Coursera course: Gut Check: Exploring Your Microbiome. V interesting so far (some of it going over my head, but getting the gist!) e.g. did you know human adult bodies have about 10 trillion human cells and about 100 trillion microbe cells in them, so on that basis we're actually only about 10% human, and 90% microbe! The more I read and listen to the more fascinating it gets and the more I appreciate the work which companies like 4d are doing. GLA
Is it too much to ask for Mark Child to provide for his loyal and long-suffering English-speaking investors: (a) a heads-up that this video has been made (b) a translation
If the notes below are correct, why is it only now that 'a letter will be sent ...' to the cooperative? Negotiations with them not yet started? What has MC's team of lawyers been doing - supposed to have been on land purchasing duties for more than 2 years.
Just been looking at the inf about 4d's presentations at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting in Nov. Anyone know if there have been posters / papers / presentations on LBPs there before. 4d really is raising the profile of these novel therapies at the highest levels.
aj001 - with a cancer update ahead of Nov conference, progress on blautix i.e. JV / pIII trial, update on covid work, work on nasdaq listing etc etc I would hope sp to be at least double where it is now within 3 months. GLA
LargeGin - totally agree. In my view sp being held back to allow big buyers to gradually buy in cheap. Buying too quick they would be unable to keep the lid on it. And holding price down shakes out weaker / short term holders looking for quick buck. All indications for 4d are positive, not least comparison with US peers' mkt caps which suggests 4d wayyyyyyyy undervalued. GLA
I think Noix has tried to do it using a simple, layman's approach. I agree though, in order for decision-making etc trials of this sort must use the agreed statistical methods. The company is happy that the results are good, and in particular good enough to design and proceed to pIII trial of blautix, which was the purpose of the pII trial.
And of course that is just 1 of many workstreams at different stages of development. e.g. We know that the important pI/II trial (MRx0518) in cancer (pre-treated solid tumours) produced statistically significant positive results - to quote 4d chief scientific officer '... unparalleled, and particularly significant in oncology ...'
Michaelhighbar - good questions and great response from the company. Enormously encouraging for the future. Just need the market to catch up. I agree with the suggestion that it would be helpful if the company could get this info out to a much wider audience. Investor relations must have ways and means of doing this ...